NanoViricides unaffected by US tariff turmoil, says CFO

Company Overview - NanoViricides is focused on developing broad-spectrum antiviral therapeutics, with its lead candidate NV-387 targeting over 90% of pathogenic viruses, including influenza, RSV, Covid, and smallpox [2][6] - The company conducts all research and development in-house in Shelton, Connecticut, making it immune to international tariff changes [4][5] Technology and Product Development - NV-387 is not a vaccine but a therapeutic drug that mimics receptor sites used by pathogenic viruses, allowing it to remain effective despite viral mutations [5][6] - The drug is based on heparan sulfate, which is utilized by more than 90% of pathogenic viruses, providing a broad-spectrum treatment option [6] Market Position and Strategy - The current U.S. administration is adopting a balanced approach towards pandemic preparedness, recognizing the importance of therapeutics alongside vaccines [7] - The U.S. Department of Agriculture's investment of approximately $100 million to combat avian influenza aligns with the company's interests, as NV-387 can address H5N1 [8][9] Clinical Trials and Future Outlook - The company is conducting Phase 2 trials for NV-387 against smallpox, following a successful Phase 1 trial with no adverse effects [10] - The company emphasizes the importance of looking towards the future and the potential of its groundbreaking technology to combat 90% of viral infections [11]